Capricor/CAPR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Capricor

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Ticker

CAPR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Beverly hills, United States

Employees

101

Capricor Metrics

BasicAdvanced
$181M
Market cap
-
P/E ratio
-$0.88
EPS
3.97
Beta
-
Dividend rate
$181M
3.97
$8.22
$2.68
8
1.57
18.314
18.314
-47.07%
-197.34%
-122.20%
6.668
9.736
9.801
389.30%
25.01%
332.95%

What the Analysts think about Capricor

Analyst Ratings

Majority rating from 5 analysts.
Buy

Capricor Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-197.95% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$4.9M
-59.17%
Net income
-$9.7M
1,285.71%
Profit margin
-197.95%
3,295.37%

Capricor Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 173.53%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.29
-$0.25
-$0.02
-$0.31
-
Expected
-$0.35
-$0.29
-$0.09
-$0.11
-$0.36
Surprise
-17.14%
-13.79%
-77.78%
173.53%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Capricor stock?

Capricor (CAPR) has a market cap of $181M as of June 25, 2024.

What is the P/E ratio for Capricor stock?

The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of June 25, 2024.

Does Capricor stock pay dividends?

No, Capricor (CAPR) stock does not pay dividends to its shareholders as of June 25, 2024.

When is the next Capricor dividend payment date?

Capricor (CAPR) stock does not pay dividends to its shareholders.

What is the beta indicator for Capricor?

Capricor (CAPR) has a beta rating of 3.97. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Capricor stock price target?

The target price for Capricor (CAPR) stock is $19.8, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Capricor stock

Buy or sell Capricor stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing